Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name TPX-4589
Synonyms
Therapy Description

TPX-4589 (LM-302) is an antibody-drug conjugate (ADC) comprising a claudin 18.2 (CLDN18.2) targeted antibody linked to monomethyl auristatin E (MMAE), which potentially inhibits proliferation of CLDN18.2-expressing tumor cells and tumor growth (Eur J Cancer 2022 Vol 174, Supp 1:S41-S42).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
TPX-4589 LM 302|LM302|LM-302|TPX 4589|TPX4589 CLDN18.2 Antibody 12 TPX-4589 (LM-302) is an antibody-drug conjugate (ADC) comprising a claudin 18.2 (CLDN18.2) targeted antibody linked to monomethyl auristatin E (MMAE), which potentially inhibits proliferation of CLDN18.2-expressing tumor cells and tumor growth (Eur J Cancer 2022 Vol 174, Supp 1:S41-S42).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT05001516 Phase Ib/II TPX-4589 Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors Recruiting USA 0
NCT05188664 Phase Ib/II Toripalimab + TPX-4589 TPX-4589 Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors Enrolling by invitation 1


Additional content available in CKB BOOST